In last trading session, Elevation Oncology Inc (NASDAQ:ELEV) saw 0.43 million shares changing hands with its beta currently measuring 1.54. Company’s recent per share price level of $3.70 trading at -$0.12 or -3.14% at ring of the bell on the day assigns it a market valuation of $180.01M. That closing price of ELEV’s stock is at a discount of -59.19% from its 52-week high price of $5.89 and is indicating a premium of 90.27% from its 52-week low price of $0.36. Taking a look at company’s average trading volume volume of 1.03 million if we extend that period to 3-months.
Elevation Oncology Inc (NASDAQ:ELEV) trade information
Upright in the red during last session for losing -3.14%, in the last five days ELEV remained trading in the green while hitting it’s week-highest on Wednesday, 05/01/24 when the stock touched $3.70 price level, adding 17.41% to its value on the day. Elevation Oncology Inc’s shares saw a change of 589.01% in year-to-date performance and have moved 2.21% in past 5-day. Elevation Oncology Inc (NASDAQ:ELEV) showed a performance of -26.88% in past 30-days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Elevation Oncology Inc (ELEV) estimates and forecasts
Statistics highlight that Elevation Oncology Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 740.91% of value to its shares in past 6 months, showing an annual growth rate of 35.07% while that of industry is 12.80. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -52.56% during past 5 years.
ELEV Dividends
Elevation Oncology Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
